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Abstract
Purpose: To determine the efficacy and safety of different prophylactic systemic 
antibiotics in adult and pediatric patients receiving chemotherapy or undergoing he-
matopoietic stem cell transplantation (HSCT).
Methods: We conducted a systematic review and performed searches of Ovid 
MEDLINE, MEDLINE in‐process and Embase; and Cochrane Central Register of 
Controlled Trials. Studies were included if patients had cancer or were HSCT re-
cipients with anticipated neutropenia, and the intervention was systemic antibacte-
rial prophylaxis. Strategies synthesized included fluoroquinolone vs no antibiotic/
nonabsorbable antibiotic; fluoroquinolone vs trimethoprim‐sulfamethoxazole; tri-
methoprim‐sulfamethoxazole vs no antibiotic; and cephalosporin vs. no antibiotic. 
Fluoroquinolone vs cephalosporin and levofloxacin vs ciprofloxacin were compared 
by network meta‐analysis. Primary outcome was bacteremia.
Results: Of 20 984 citations screened, 113 studies comparing prophylactic antibi-
otic to control were included. The following were effective in reducing bacteremia: 
fluoroquinolone vs no antibiotic/nonabsorbable antibiotic (risk ratio (RR) 0.56, 
95% confidence interval (CI) 0.41‐0.76), trimethoprim‐sulfamethoxazole vs no 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
75
21
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
   | 4537EGAN Et Al
1 |  INTRODUCTION
Bacteremia and infectious complications are important 
causes of morbidity and death in children and adults re-
ceiving intensive chemotherapy and undergoing hema-
topoietic stem cell transplant (HSCT).1,2 A number of 
preventative strategies to reduce infection in neutropenic 
patients have been investigated, including granulocyte 
infusions,3 granulocyte colony‐stimulating factor (G‐
CSF),4,5 nonabsorbable antibiotics,6 and systemic antibi-
otics.7 The potential efficacy of systemically administered 
antibiotic prophylaxis is of great interest.7 However, there 
is uncertainty regarding the optimal prophylactic antibiotic 
class in terms of efficacy and adverse effects. Outcomes 
important in this decision include measures of prophylaxis 
efficacy including bacteremia, fever, and mortality. In ad-
dition, the evaluation of potential adverse effects should 
be considered including antibiotic resistance, Clostridium 
difficile infection, and invasive fungal disease. Also, ad-
verse effects associated with specific antibiotic classes 
such as fluoroquinolone‐related musculoskeletal toxicities 
warrant consideration.
There are many randomized trials that have evaluated 
systemic antibiotic prophylaxis in patients with cancer and 
HSCT recipients. Furthermore, the Children's Oncology 
Group recently published a large randomized trial of 624 
high‐risk pediatric patients evaluating levofloxacin prophy-
laxis, thus substantially increasing the pediatric evidence 
base around antibiotic prophylaxis.8 Therefore, we reasoned 
it would be timely to perform a systematic review of antibi-
otic prophylaxis in order to inform a future evidence‐based 
clinical practice guideline. Also, since treatment‐related 
mortality is declining over time,9 the impact of prophy-
laxis on mortality may be changing, thus increasing the 
importance of conducting the analysis with recently con-
ducted studies.
Consequently, our objectives were to determine the effi-
cacy and safety of different prophylactic systemic antibiotics 
in patients receiving chemotherapy or undergoing HSCT.
2 |  METHODS
For this systematic review, we followed the Preferred 
Reporting Items for Systematic Reviews and Meta‐Analyses 
(PRISMA) recommendations for reporting.10
2.1 | Data sources and searches
With the assistance of a library scientist, we searched Ovid 
MEDLINE, MEDLINE in‐process and Embase; and Wiley 
Cochrane Central Register of Controlled Trials for articles 
indexed up to 26 November 2018. The search strategy in-
cluded the Medical Subject Heading terms and text words 
that identified patients with cancer or HSCT recipients re-
ceiving antibacterial prophylaxis (Supplemental Appendix 
S1 contains the full search strategy). The resultant set was 
limited to randomized trials published in 1980 or later. There 
was no restriction by language.
2.2 | Study selection
We defined inclusion and exclusion criteria a priori. 
Studies were included if the manuscript was a fully pub-
lished primary randomized or quasi‐randomized trial with 
a parallel group design; if the study compared the admin-
istration of a systemic antibacterial agent to any control 
group as prophylaxis; and if at least 90% of participants 
antibiotic (RR 0.59, 95% CI 0.41‐0.85) and cephalosporin vs no antibiotic (RR 0.30, 
95% CI 0.16‐0.58). Fluoroquinolone was not significantly associated with increased 
Clostridium difficile infection (RR 0.62, 95% CI 0.31‐1.24) or invasive fungal disease 
(RR 1.28, 95% CI 0.79‐2.08) but did increase resistance to fluoroquinolone among 
bacteremia isolates (RR 3.35, 95% CI 1.12 to 10.03). Heterogeneity in fluoroqui-
nolone effect on bacteremia was not explained by evaluated study, population, or 
methodological factors. Network meta‐analysis revealed no direct comparisons for 
pre‐specified analyses; superior regimens were not identified.
Conclusions: Fluoroquinolone, trimethoprim‐sulfamethoxazole, and cephalosporin 
prophylaxis reduced bacteremia. A clinical practice guideline to facilitate prophylac-
tic antibiotic decision‐making is required.
K E Y W O R D S
antibiotic prophylaxis, cancer, meta‐analysis, randomized trials
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were patients undergoing chemotherapy for cancer or 
HSCT for any indication. As trimethoprim‐sulfamethoxa-
zole can be administered as both prophylaxis against bacte-
rial infection (daily) and Pneumocystis jiroveci pneumonia 
(intermittently), systemic antibiotic prophylaxis with tri-
methoprim‐sulfamethoxazole required administration at 
least once daily. Reasons for excluding studies were as fol-
lows: (a) not a full text publication; (b) not a randomized 
trial with a parallel group design; (c) less than 90% patients 
receiving chemotherapy for cancer or undergoing HSCT; 
(d) intervention not a systemic antibacterial agent adminis-
tered for prophylaxis; (e) antibacterial agent given as peri‐
procedural prophylaxis only; (e) duplicate study; and (f) 
published before 1980.
Two reviewers (GE and PDR) independently evaluated 
the titles and abstracts of publications identified by the 
search strategy and all potentially relevant publications were 
retrieved in full. Disagreements between the two reviewers 
were resolved by consensus and adjudicated by a third re-
viewer (LS) if required. We described agreement with study 
inclusion between the two reviewers using the kappa statistic 
and agreement was defined as slight (0 to 20%), fair (21 to 
40%), moderate (41 to 60%), substantial (61 to 80%) or al-
most perfect (81 to 100%).11
2.3 | Data abstraction and 
methodological approach
Two reviewers (GE and PDR) abstracted all data in duplicate 
and any discrepancies were resolved by consensus. A third 
reviewer (LS) resolved any outstanding discrepancies if re-
quired. Efficacy outcome measures were bacteremia, fever, 
neutropenic fever, infection‐related mortality, and overall 
mortality. Episodes of fever and neutropenic fever were ab-
stracted into different categories as some studies described 
any fever irrespective of neutrophil count while other stud-
ies only described fever if it occurred during neutropenia. 
Adverse outcome measures were C difficile infection, in-
vasive fungal disease (as defined by each study), musculo-
skeletal adverse effects and antibiotic resistance. Antibiotic 
resistance to the intervention antibiotic among all bacteremia 
isolates tested was abstracted from intervention and control 
groups. This outcome was not evaluated in studies comparing 
two systemic prophylactic antibiotics.
Study‐level factors collected included year of study pub-
lication, number of randomized groups, country of study 
conduct, age group (adult, pediatric or both), age range, treat-
ment group (cancer patients receiving chemotherapy only, 
HSCT only, or both chemotherapy and HSCT) and cancer 
diagnosis or HSCT type. Pediatric studies were defined as 
those in which all participants were less than 25 years of age 
while adult studies were defined as those in which all partic-
ipants were older than 15 years of age.
2.4 | Interventions evaluated
Based upon the available data and clinical relevance, com-
parisons at the group level focused broadly on fluoroqui-
nolone‐based and non‐fluoroquinolone‐based evaluations. 
The fluoroquinolone analysis concentrated on the com-
parison between fluoroquinolone vs no antibiotic or non-
absorbable antibiotic. These control groups were combined 
as we presumed that nonabsorbable antibiotic would have 
minimal impact on the efficacy and safety outcomes of in-
terest, and combining them would improve power to iden-
tify sources of heterogeneity. However, we also presented 
the analysis stratified by no antibiotic and nonabsorbable 
antibiotic control groups separately. No antibiotic controls 
included both placebo and usual care (no antibiotic prophy-
laxis). Next, we evaluated the impact of levofloxacin and 
ciprofloxacin specifically vs no antibiotic. Finally, we com-
pared fluoroquinolone vs trimethoprim‐sulfamethoxazole 
prophylaxis.
In terms of non‐fluoroquinolone‐based comparisons, 
we compared trimethoprim‐sulfamethoxazole vs no anti-
biotic, cephalosporin vs no antibiotic, parenteral glycopep-
tide vs no antibiotic and rifampin plus fluoroquinolone vs 
fluoroquinolone.
For trials with more than two study arms the following 
hierarchical rules were used to determine the intervention 
and control groups for conventional meta‐analysis although 
all arms were used for network meta‐analysis. Control 
group was chosen in the following order: (a) placebo; (b) 
no antibiotic; and (c) nonabsorbable antibiotic. If differ-
ent fluoroquinolones were examined, the fluoroquinolone 
with the broadest spectrum of activity was considered the 
intervention.
2.5 | Assessment of risk of bias
Two reviewers (GE and PDR) assessed study quality and any 
discrepancies were resolved by consensus. Outstanding dis-
crepancies were resolved by a third reviewer (LS) if required. 
Study quality was evaluated at the level of the study using the 
Cochrane Collaboration's tool for assessing the risk of bias in 
randomized trials.12 It includes the following domains rele-
vant to internal validity: selection bias, performance bias, de-
tection bias, attrition bias, and reporting bias. We evaluated 
the following sources of bias related to these domains: ran-
dom number generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, 
incomplete outcome data, and selective outcome reporting.
2.6 | Statistical methods
We combined data at the study level for this meta‐analy-
sis. Synthesis was conducted when there were at least three 
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studies that reported an outcome for a main comparison and 
at least two studies that reported an outcome within each 
stratum in the stratified analysis. Data were synthesized 
using the risk ratio (RR) as the effect measure with its 95% 
confidence interval (CI). The Mantel‐Haenszel approach 
was used to estimate treat effects and effects were weighted 
by the inverse variance. In this analysis, RR < 1 suggests 
that the intervention is better than the control group. As 
we anticipated heterogeneity between studies, a random 
effects model (DerSimonian and Laird)13 was used for all 
analyses. Statistical heterogeneity between trials was as-
sessed using the I2 value, which describes the percentage 
of total variation across studies due to heterogeneity rather 
than chance.12
For stratified analysis, we a priori prioritized evaluation 
of fluoroquinolone based on the large number of available 
trials, broad Gram‐negative coverage and fewer myelosup-
pression concerns.7 We evaluated the following factors to 
identify if they could explain heterogeneity in prophylaxis 
effect: treatment group (chemotherapy, HSCT or both), 
age of participants (adult or pediatric), year of publication 
(<2000 vs  ≥2000), risk of bacteremia in control arm (< 
median among the whole cohort vs  ≥  median), adequate 
sequence generation, and adequate allocation concealment. 
We determined if the effect varied by subgroup through 
evaluation of the P value for interaction. Only stratified 
analyses for the primary outcome of bacteremia and the key 
secondary outcome of overall survival were conducted to 
limit the number of tests performed.
For network meta‐analysis, we focused on comparisons of 
interest in which direct comparison was limited or not avail-
able because of the paucity/absence of head‐to‐head trials. 
These included comparison of fluoroquinolone vs cephalo-
sporin and levofloxacin vs ciprofloxacin. Only studies that 
assessed any of these antibiotic types were included in the 
network. Network meta‐analysis was restricted to the primary 
outcome of bacteremia.
Potential publication bias was explored by visual in-
spection of funnel plots when at least 10 studies were avail-
able.12 Funnel plots graphically display the effect measure 
on the X‐axis and precision on the Y‐axis. Asymmetry 
with an absence of studies in a lower quadrant may indicate 
publication bias. In the event of such asymmetry, we used 
the trim and fill technique to describe the potential impact 
of such bias. With this approach, outlying studies are re-
moved and hypothetical negative studies with equal weight 
are added.12
We synthesized data for conventional meta‐analy-
sis using Review Manager 5.3 (Cochrane Collaboration, 
Nordic Cochrane Centre). Network meta‐analysis was con-
ducted using a Bayesian approach using R through the li-
brary gemtc.
F I G U R E  1  Flow diagram depicting 
study identification, selection, and reasons 
for exclusion
FLWDWLRQVVFUHHQHGE\WLWOHDEVWUDFW GXSOLFDWHVUHPRYHGSDSHUVUHWULHYHGIRUIXOOWH[WHYDOXDWLRQ H[FOXGHG&RQIHUHQFHDEVWUDFWV1RWDUDQGRPL]HGWULDOZLWKDSDUDOOHOJURXSGHVLJQ,QWHUYHQWLRQQRWV\VWHPLFDQWLELRWLFIRUSURSK\OD[LV$QWLELRWLFJLYHQDVSHULSURFHGXUDOSURSK\OD[LV3XEOLVKHGEHIRUH'XSOLFDWH1RWUHWULHYDEOH
SRWHQWLDOO\UHOHYDQWUHIHUHQFHVLGHQWLILHG
LQFOXGHGVWXGLHV
FLWDWLRQVH[FOXGHGDVGLGQRWPHHWHOLJLELOLW\FULWHULD
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3 |  RESULTS
The flow of study identification and selection is illustrated 
in Figure 1. There were 20,984 citations identified by the 
search strategy, of which 194 were retrieved for full‐text 
evaluation. Of these papers, 113 met the eligibility cri-
teria and were included in the systematic review. Figure 
1 describes reasons for exclusion. Agreement in study 
inclusion between the two reviewers was almost perfect 
with kappa = 97.9% (95% CI 95.0‐100).
Table 1 describes the characteristics of the 113 in-
cluded studies with 13,677 patients; details are shown in 
Supplemental Appendix S2. There were 73 studies (65%) 
consisting of patients with cancer receiving chemotherapy, 
19 (17%) consisting of patients undergoing HSCT and 21 
(18%) consisting of both chemotherapy and HSCT recipients. 
Only 13 (12%) studies were solely pediatric. Trials were con-
ducted in 20 different countries. The most common antibi-
otic comparison available for synthesis was fluoroquinolone 
vs no antibiotic or nonabsorbable antibiotic (n = 29), which 
were divided into no antibiotic (n = 24) and nonabsorbable 
antibiotic (n = 5) control groups. The second most common 
antibiotic comparison available for synthesis was trimetho-
prim‐sulfamethoxazole vs no antibiotic (n = 18).
Table 2 shows the synthesized outcomes for fluoro-
quinolone‐based comparisons. When compared to no 
antibiotic or nonabsorbable antibiotic controls, fluoroquino-
lone significantly reduced bacteremia (RR 0.56, 95% CI 
0.41‐0.76)  (Figure 2), fever (RR 0.78, 95% CI 0.66‐0.93), 
neutropenic fever (RR 0.87, 95% CI 0.82‐0.93) and infec-
tion‐related mortality (RR 0.64, 95% CI 0.42‐0.98) but did 
not significantly reduce overall mortality (RR 0.85, 95% CI 
0.65‐1.11). Fluoroquinolone prophylaxis was not associated 
with a significant increase in C difficile infection, invasive 
fungal disease or musculoskeletal toxicity. However, fluoro-
quinolone resistance was increased among bacteremia iso-
lates in the prophylaxis group (RR 3.35, 95% CI 1.12‐10.03). 
These results were almost identical to comparison of fluoro-
quinolone vs. no antibiotic control separately. In evaluating 
specific fluoroquinolones, levofloxacin significantly reduced 
bacteremia (RR 0.54, 95% CI 0.44‐0.67), fever (RR 0.63, 
95% CI 0.42‐0.95) and neutropenic fever (RR 0.87, 95% CI 
0.80‐0.95) without significantly reducing overall mortality 
(RR 0.79, 95% CI 0.52‐1.20) while ciprofloxacin did not 
significantly reduce bacteremia, neutropenic fever or overall 
mortality compared to no antibiotic. To evaluate whether spe-
cific fluoroquinolone (levofloxacin, ciprofloxacin, norflox-
acin, or ofloxacin) explained heterogeneity in the effect of 
fluoroquinolone prophylaxis vs no antibiotic to reduce bac-
teremia, the P value for interaction was 0.74. Comparison 
between fluoroquinolone and trimethoprim‐sulfamethoxaz-
ole did not show significant differences in bacteremia, fever, 
infection‐related mortality, or invasive fungal disease.
Table 3 shows the synthesized outcomes for non‐fluoro-
quinolone‐based comparisons. When compared to no antibi-
otic, trimethoprim‐sulfamethoxazole significantly reduced 
bacteremia (RR 0.59, 95% CI 0.41‐0.85) and infection‐related 
mortality (RR 0.61, 95% CI 0.39‐0.94) without significantly 
reducing overall mortality (RR 0.61, 95% CI 0.28‐1.33). 
However, trimethoprim‐sulfamethoxazole prophylaxis in-
creased resistance to this agent in bacteremia isolates (RR 
T A B L E  1  Characteristics of included studies in systematic 
review (N = 113)
Characteristic and strata No. studies (%)
Study population characteristics  
Treatment  
Cancer patients receiving chemother-
apy only
73 (65%)
Hematopoietic stem cell transplanta-
tion only
19 (17%)
Both chemotherapy and transplantation 21 (18%)
Age participants  
Adult 75 (66%)
Pediatric 13 (12%)
Both 18 (16%)
Not stated 7 (6%)
Interventions included in synthesisa  
Fluoroquinolone vs no antibiotic or non-
absorbable antibiotic
29
Fluoroquinolone vs no antibiotic 24
Levofloxacin vs no antibiotic 5
Ciprofloxacin vs no antibiotic 5
Fluoroquinolone vs non‐absorbable 
antibiotic
5
Fluoroquinolone vs 
trimethoprim‐sulfamethoxazole
8
Trimethoprim‐sulfamethoxazole vs no 
antibiotic
18
Cephalosporin vs no antibiotic 4
Parenteral glycopeptide vs no antibiotic 4
Rifampin plus fluoroquinolone vs 
fluoroquinolone
3
Risk of bias  
Adequate sequence generation 24 (21%)
Adequate allocation concealment 21 (19%)
Participants and personnel blinded 27 (24%)
Outcome assessors blinded 11 (10%)
Lack of attrition bias 70 (62%)
Free of selective reporting 33 (29%)
aNo antibiotic includes placebo and usual care (no antibiotic prophylaxis) 
control groups. 
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2.91, 95% CI 1.65‐5.12). Cephalosporin prophylaxis con-
sisted of cefepime (n  =  1) and ceftriaxone (n  =  3); it sig-
nificantly reduced bacteremia (RR 0.30, 95% CI 0.16‐0.58) 
and fever (RR 0.83, 95% CI 0.71‐0.98) but did not signifi-
cantly reduce infection‐related mortality (RR 1.03, 95% CI 
0.27‐3.95) or overall mortality (RR 1.58, 95% CI 0.72‐3.45). 
Glycopeptide prophylaxis did not significantly reduce bac-
teremia or infection‐related mortality. Finally, the addition 
of rifampin to fluoroquinolone significantly reduced the risk 
of bacteremia compared to fluoroquinolone alone (RR 0.36, 
95% CI 0.17‐0.77).
Table 4 shows the stratified analyses for fluoroquinolone 
vs no antibiotic or nonabsorbable antibiotic for the two out-
comes of bacteremia and overall mortality. Heterogeneity in 
the prophylaxis effect against bacteremia was not explained 
by treatment (chemotherapy, HSCT or both), age of partici-
pants (adult or pediatric), year of publication (early or late), 
risk of bacteremia in the control arm (low or high), adequate 
sequence generation or adequate allocation concealment. 
Similarly, heterogeneity in the treatment effect for overall 
mortality was not explained by treatment, year of publica-
tion, adequate sequence generation or adequate allocation 
concealment.
Potential publication bias was observed for the comparison 
of fluoroquinolone vs. no antibiotic or nonabsorbable antibi-
otic controls for the outcomes of bacteremia (Supplemental 
Appendix S3), fever (not shown) and overall mortality 
(Supplemental Appendix S4) but not infection‐related mor-
tality (not shown). The comparison of trimethoprim‐sulfame-
thoxazole vs no antibiotic did not suggest publication bias for 
the outcome of infection‐related mortality, the only outcome 
amenable to funnel plot visualization. We applied the trim 
and fill approach for the comparison of fluoroquinolone vs 
no antibiotic or nonabsorbable antibiotic controls for the out-
come of bacteremia. When the outlying study was removed 
and when a hypothetical negative study with equal weight 
was added, the resultant estimates remained significant (RR 
0.57, 95% CI 0.42‐0.77 and RR 0.57, 95% CI 0.42‐0.78, 
respectively).
In terms of the network meta‐analysis, 33 studies re-
porting on bacteremia were included after limiting to stud-
ies that evaluated fluoroquinolone or cephalosporin in any 
arm and removing studies comparing the same specific an-
tibiotic (for example, compared different doses of the same 
antibiotic). Supplemental Appendix S5 and Appendix S6 
illustrate the networks and show direct and indirect com-
parisons available. In the comparison of fluoroquinolone 
vs. cephalosporin prophylaxis (Supplemental Appendix 
S5), there were no studies that directly compared these two 
antibiotic types. Cephalosporin, when compared to fluo-
roquinolone, did not significantly reduce bacteremia by 
network meta‐analysis (RR 0.58, 95% credible limit 0.27 
to 1.2). In the comparison of levofloxacin vs ciprofloxacin 
(Supplemental Appendix S6), there were no studies that di-
rectly compared these two antibiotic types. Levofloxacin 
did not significantly reduce bacteremia when compared 
to ciprofloxacin by network meta‐analysis (RR 0.79, 95% 
credible limit 0.42 to 1.5).
4 |  DISCUSSION
In this systematic review, we found that fluoroquinolone 
prophylaxis was effective at reducing bacteremia, fever and 
F I G U R E  2  Forest plot of bacteremia rate among studies comparing any fluroquinolone vs no antibiotic or nonabsorbable antibiotic. 
Squares to the left of the vertical line mean that bacteremia was reduced with fluoroquinolone. Horizontal lines through the squares represent 95% 
confidence intervals (CIs). The size of the squares reflects each study's relative weight, and the diamond represents the aggregate risk ratio and 95% 
CI
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T A B L E  2  Synthesized outcomes for comparisons of fluoroquinolone prophylaxisa
Comparison and outcomes
Number 
studies
Number 
patients RR 95% CI I2 P
A. Fluoroquinolone vs No Antibiotic or Non‐absorbable Antibiotic Comparisons
1. Fluoroquinolone vs either no antibiotic or non‐absorbable antibiotic
Bacteremia 14 2154 0.56 0.41‐0.76 58% 0.0002
Fever 12 3231 0.78 0.66‐0.93 84% 0.005
Neutropenic fever 9 1302 0.87 0.82‐0.93 0% < 0.0001
Infection‐related mortality 19 4376 0.64 0.42‐0.98 0% 0.04
Overall mortality 17 3742 0.85 0.65‐1.11 15% 0.24
C difficile infection 3 798 0.62 0.31‐1.24 0% 0.17
Invasive fungal disease 8 1242 1.28 0.79‐2.08 0% 0.31
Musculoskeletal adverse effects 3 1272 0.70 0.44‐1.12 0% 0.14
Antibiotic resistance 4 147 3.35 1.12‐10.03 64% 0.03
2. Fluoroquinolone vs no antibiotic
a) All fluoroquinolone vs no antibiotic
Bacteremia 14 2154 0.56 0.41‐0.76 58% 0.0002
Fever 9 2996 0.70 0.57‐0.86 71% 0.0008
Neutropenic fever 8 1174 0.88 0.82‐0.95 0% 0.0008
Infection‐related mortality 16 4016 0.72 0.45‐1.16 0% 0.17
Overall mortality 15 3444 0.86 0.62‐1.17 24% 0.34
C difficile infection 3 798 0.62 0.31‐1.24 0% 0.17
Invasive fungal disease 6 1032 1.25 0.75‐2.08 0% 0.39
Musculoskeletal adverse effects 3 1272 0.66 0.39‐1.13 0% 0.13
Antibiotic resistance 4 147 3.35 1.12‐10.03 64% 0.03
b) Levofloxacin vs no antibiotic
Bacteremia 3 1336 0.54 0.44‐0.67 0% <0.00001
Fever 3 2490 0.63 0.42‐0.95 73% 0.03
Neutropenic fever 3 880 0.87 0.80‐0.95 0% 0.002
Infection‐related mortality 4 3101 0.72 0.36‐1.43 0% 0.35
Overall mortality 3 2488 0.79 0.52‐1.20 47% 0.27
c) Ciprofloxacin vs no antibiotic
Bacteremia 3 148 0.88 0.26‐2.97 24% 0.84
Neutropenic fever 3 203 0.85 0.58‐1.25 61% 0.41
Infection‐related mortality 4 253 0.65 0.18‐2.31 0% 0.51
Overall mortality 3 218 1.70 0.22‐13.01 43% 0.61
3. Fluoroquinolone vs non‐absorbable antibiotic
Fever 3 235 0.98 0.91‐1.05 0% 0.50
Infection‐related mortality 3 360 0.43 0.18‐1.05 0% 0.06
B. Fluoroquinolone vs Trimethoprim‐sulfamethoxazole
Bacteremia 7 583 0.86 0.48‐1.54 66% 0.60
Fever 3 291 0.65 0.31‐1.37 89% 0.26
Infection‐related mortality 6 541 1.10 0.50‐2.39 0% 0.82
Invasive fungal disease 6 541 0.78 0.35‐1.75 0% 0.55
Abbreviations: CI, confidence interval; RR, risk ratio.
aNo antibiotic includes placebo and usual care (no antibiotic prophylaxis) control groups. 
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infection‐related mortality without significantly increas-
ing C difficile infection, invasive fungal disease or muscu-
loskeletal adverse effects when compared to no antibiotic 
or nonabsorbable antibiotic controls. However, fluoroqui-
nolone prophylaxis increased fluoroquinolone resistance in 
bacteremia isolates. We also found that at least once daily 
trimethoprim‐sulfamethoxazole prophylaxis was effective 
in reducing bacteremia and infection‐related mortality when 
compared to no antibiotic controls although it did increase 
trimethoprim‐sulfamethoxazole resistance in bacteremia iso-
lates. Cephalosporin prophylaxis reduced bacteremia but did 
not significantly reduce infection‐related mortality, with an-
tibiotic resistance not being evaluable. The fluoroquinolone 
prophylaxis effect was similar among sub‐groups evaluated 
related to bacteremia and overall survival. Finally, fluoroqui-
nolone vs cephalosporin and levofloxacin vs ciprofloxacin 
had similar effects in terms of bacteremia prevention in net-
work meta‐analysis.
Our systematic review is important as it not only includes 
the most recent randomized trials, but in addition, evaluates 
heterogeneity in the fluoroquinolone prophylaxis effect and 
includes a network meta‐analysis to contrast therapies in 
which no direct comparative trials exist. Prior systematic re-
views focused on specific patient populations such as those 
with hematological malignancy14 and HSCT15 or specific 
antibiotic classes such as fluoroquinolone.16 In contrast, our 
review included all systemic antibiotics and all cancer ther-
apies including HSCT. The only published broadly inclusive 
systematic review does not include data from trials published 
in the last eight years (included studies until 2010).7
We did not find that the following explained heteroge-
neity in the effect of fluoroquinolone prophylaxis to reduce 
bacteremia: patient group (chemotherapy, HSCT or both), 
age (adult or pediatric), year of publication (early or late), 
or risk of bacteremia in the control arm (low or high). This 
suggests that prophylaxis can be considered in a broad group 
of patients. However, it is important to note that we evaluated 
RRs in this study and that as the prevalence of bacteremia 
decreases, the RR associated with prophylaxis may remain 
constant but the absolute risk reduction could be diminished 
to the point that prophylaxis is no longer worthwhile. For 
example, a RR of 0.5 represents both decreasing bacteremia 
risk from 80% to 40% (probably worthwhile) and decreasing 
risk from 0.2% to 0.1% (probably not worthwhile).
T A B L E  3  Synthesized Outcomes for Non‐Fluoroquinolone‐based Comparisonsa
Comparison and 
outcomes Number studies Number patients RR 95% CI I2 P
A. Trimethoprim‐sulfamethoxazole vs No Antibiotic
Bacteremia 7 735 0.59 0.41‐0.85 0% 0.005
Fever 5 388 0.77 0.56‐1.07 91% 0.11
Infection‐related 
mortality
13 984 0.61 0.39‐0.94 0% 0.03
Overall mortality 5 268 0.61 0.28‐1.33 32% 0.21
Invasive fungal 
disease
7 744 1.19 0.43‐3.27 27% 0.74
Antibiotic resistance 5 68 2.91 1.65‐5.12 0% 0.0002
B. Cephalosporin vs No Antibiotic
Bacteremia 4 337 0.30 0.16‐0.58 42% 0.0004
Fever 4 337 0.83 0.71‐0.98 65% 0.03
Infection‐related 
mortality
3 316 1.03 0.27‐3.95 0% 0.96
Overall mortality 3 272 1.58 0.72‐3.45 0% 0.26
C. Parenteral Glycopeptide vs No Antibiotic
Bacteremia 3 170 0.45 0.08‐2.66 84% 0.38
Infection‐related 
mortality
3 273 1.13 0.30‐4.23 10% 0.85
D. Rifampin Plus Fluoroquinolone vs Fluoroquinoloneb
Bacteremia 3 236 0.36 0.17‐0.77 0% 0.008
Abbreviations: CI, confidence interval; RR, risk ratio.
aNo antibiotic includes placebo and usual care (no antibiotic prophylaxis) control groups. 
bNo events for either infection‐related mortality or overall mortality for two of three studies. 
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We found that fluoroquinolone prophylaxis did not 
reduce overall mortality either among the entire cohort 
or among different sub‐groups. We also found evidence 
of publication bias in this outcome, further supporting a 
lack of impact on survival. In contrast to our results, one 
previous meta‐analysis by Gafter‐Gvili demonstrated that 
fluoroquinolone prophylaxis significantly reduced over-
all mortality.7 Interestingly, three other systematic re-
views have not shown a statistically significant reduction 
in overall mortality associated with fluoroquinolone pro-
phylaxis.14-16 Differences between the Gafter‐Gvili review 
and ours include the following items. Our review included 
T A B L E  4  Stratified analyses for fluoroquinolone vs no antibiotic or nonabsorbable antibiotic for bacteremia and overall mortalitya
Subgroup
Number 
studies
Number 
patients RR 95% CI I2 P
Outcome of bacteremia            
Treatment           Pint = 0.75
Chemotherapy only 8 606 0.46 0.30‐0.70 0% 0.0003
Stem cell transplantation only 3 187 0.48 0.13‐1.77 72% 0.27
Both chemotherapy and 
transplantation
3 1361 0.55 0.45‐0.67 0% <0.0001
Age participants           Pint = 0.67
Adult 11 1396 0.54 0.36‐0.79 66% 0.002
Pediatric 2 708 0.66 0.27‐1.63 22% 0.37
Year of publication           Pint = 0.29
Earlier than 2000 8 554 0.46 0.31‐0.68 0% 0.0001
In or later than 2000 6 1600 0.63 0.42‐0.95 76% 0.03
Risk bacteremia in control group           Pint = 0.63
<27% (median value) 7 1065 0.52 0.39‐0.70 0% <0.0001
≥27% 7 1089 0.60 0.38‐0.93 76% 0.02
Adequate sequence generation           Pint = 0.35
Yes 6 1570 0.62 0.40‐0.96 78% 0.03
No 8 584 0.47 0.32‐0.69 0% 0.0001
Adequate allocation concealment           Pint = 0.48
Yes 5 895 0.64 0.35‐1.17 76% 0.15
No 9 1259 0.51 0.41‐0.64 0% <0.00001
Outcome of overall mortality            
Treatment           Pint = 0.27
Chemotherapy only 11 2551 0.95 0.70‐1.29 17% 0.74
Stem cell transplantation only 2 84 0.31 0.01‐7.45 NAb 0.47
Both chemotherapy and 
transplantation
4 1107 0.60 0.36‐1.00 0% 0.05
Year of Publication           Pint = 0.75
Earlier than 2000 9 724 0.89 0.57‐1.38 0% 0.59
In or later than 2000 8 3018 0.80 0.51‐1.26 44% 0.34
Adequate sequence generation           Pint = 0.14
Yes 6 2625 0.63 0.41‐0.97 0% 0.03
No 11 1117 0.97 0.67‐1.41 22% 0.87
Adequate allocation concealment           Pint = 0.89
Yes 6 1957 0.80 0.51‐1.26 0% 0.33
No 11 1785 0.83 0.56‐1.25 32% 0.37
Abbreviations: CI, confidence interval; Pint, P value for interaction, indicating subgroup heterogeneity; RR, risk ratio.
aNo antibiotic includes placebo and usual care (no antibiotic prophylaxis) control groups. 
bOne study had zero events in both arms. 
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more recent studies and restricted the fluoroquinolone 
analysis to studies that only administered fluoroquinolone 
in the intervention group. Conversely, the Gafter‐Gvili re-
view included combination antibiotics with a fluoroquino-
lone as one component of the intervention. This different 
definition of the intervention group is important as our sys-
tematic review showed that the combination of rifampin 
and fluoroquinolone was better than fluoroquinolone alone 
in reducing bacteremia.
In our conventional meta‐analysis, the effect of levo-
floxacin vs no antibiotic to reduce bacteremia was RR 0.54 
while the effect of ciprofloxacin vs no antibiotic to reduce 
bacteremia was RR 0.88. The P value for interaction for the 
analysis of fluoroquinolone type was not significant. In sup-
port of this finding, network meta‐analysis failed to show a 
difference between levofloxacin and ciprofloxacin. However, 
it is important to emphasize that network meta‐analysis may 
be problematic when patients, controls or interventions are 
heterogeneous.17 While clear differences in the population 
between the levofloxacin and ciprofloxacin studies were not 
evident, we cannot exclude incoherence, or important differ-
ences between direct and indirect estimates, as we lacked di-
rect comparative data.
It is important to note that these studies evaluated the ef-
ficacy and adverse effects of systemic antibiotic prophylaxis 
when administered within a finite time frame of a clinical 
trial among enrolled participants. An important knowledge 
gap is the long‐term impact on effectiveness, adverse effects, 
and resistance outcomes when prophylaxis is administered 
as routine care over multiple treatment cycles in a universal 
prophylaxis strategy. These outcomes will be important to 
measure in future research.
The strengths of our review include its timely and com-
prehensive nature as well as its rigorous methodology. 
Furthermore, inclusion of a network meta‐analysis is an-
other strength. However, this review must be interpreted in 
light of its weaknesses. First, we did not have access to in-
dividual level data, which could have allowed better identi-
fication of sub‐groups more likely to benefit (or more likely 
to be harmed) from prophylaxis. Second, as with all meta‐
analysis, there is the potential for bias in terms of which 
outcomes were reported in individual trials. Third, some 
syntheses such as the evaluation of C difficile infection in-
cluded few or no studies, thus limiting or precluding the 
ability to detect an effect. Fourth, we were not able to syn-
thesize results by neoplasm type based upon how studies 
were conducted and reported. Finally, we measured antibi-
otic resistance only against the intervention being evalu-
ated. There are two important issues with this approach. 
First, we did not measure if resistance rates in the control 
group were increased, which is plausible with greater en-
vironmental exposure to an antibiotic. Second, we did not 
evaluate resistance to other antibiotics in either group.
In conclusion, fluoroquinolone, trimethoprim‐sulfame-
thoxazole and cephalosporin prophylaxis reduced bacteremia 
but did not significantly reduce overall mortality. A clinical 
practice guideline to facilitate prophylactic antibiotic deci-
sion‐making is required.
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